↑ 疾患リストへ ← 戻る

 166. 弾性線維性仮性黄色腫 [臨床試験数:9,薬物数:17(DrugBank:5),標的遺伝子数:5,標的パスウェイ数:25] 

Searched query = "Pseudoxanthoma elasticum"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-004021-16-ES31/10/20187 January 2019Response to oral lansoprazole in patients with Pseudoxanthoma ElasticumResponse to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - FIM-PXE-2016-01Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
MedDRA version: 19.1 Level: PT Classification code 10037150 Term: Pseudoxanthoma elasticum System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Lansoprazole
Pharmaceutical Form: Capsule
INN or Proposed INN: Lansolprazole
CAS Number: 103577-45-3
Other descriptive name: LANSOPRAZOLE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)AuthorisedFemale: yes
Male: yes
20Phase 2Spain
2EUCTR2018-001492-20-FI20/06/201820 August 2018Pyrophosphate therapy in PXE diseasePseudoxanthoma elasticum – supplementation therapy of pyrophosphate deficiencyPseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SODIUM ACID PYROPHOSPHATE
Product Code: CAS No.: 7758-16-9
Tampere university hospitalAuthorisedFemale: yes
Male: yes
100Phase 2;Phase 3Finland
3NCT02537054September 201520 May 2019Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: AfliberceptUniversity Hospital, BonnNot recruiting18 Years65 YearsAll15Phase 2Germany
4EUCTR2014-005263-33-DE29/04/201510 September 2018Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumIntravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNePChoroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0 Level: PT Classification code 10037150 Term: Pseudoxanthoma elasticum System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Eylea
Pharmaceutical Form: Solution for injection
Medizinische Fakultät der Universität BonnNot RecruitingFemale: yes
Male: yes
15Phase 2Germany
5EUCTR2013-001421-55-FR13/06/201311 December 2017An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEAn open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEChoroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy
MedDRA version: 18.0 Level: HLGT Classification code 10047060 Term: Retina, choroid and vitreous haemorrhages and vascular disorders System Organ Class: 10015919 - Eye disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002A
Pharmaceutical Form: Solution for injection
INN or Proposed INN: RANIBIZUMAB
CAS Number: 347396-82-1
Current Sponsor code: RFB002
Concentration unit: µl microlitre(s)
Concentration type: equal
Concentration number: 50-
Novartis Pharma S.A.SNot RecruitingFemale: yes
Male: yes
500Phase 3France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01525875August 20121 February 2016Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: Magnesium Oxide;Drug: PlaceboMark LebwohlNot recruiting18 YearsN/ABoth44Phase 2United States
7NCT00510965August 200719 February 2015Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)Choroidal NeovascularizationDrug: Intravitreal injection ranibizumabUniversity Hospital, BonnNovartisNot recruiting18 Years65 YearsBoth10Phase 2Germany
8EUCTR2006-006231-49-DE24/07/200719 March 2012Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease
MedDRA version: 8.1 Level: LLT Classification code 10037150 Term: Pseudoxanthoma elasticum
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002
Pharmaceutical Form: Solution for injection
INN or Proposed INN: ranibizumab
Current Sponsor code: CRFB002ADE03
Other descriptive name: RFB002, rhuFab V2
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Department of Ophthalmology, Bonn UniversityAuthorisedFemale: yes
Male: yes
Germany
9NCT00470977May 200719 February 2015Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related MaculopathyTreatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)Coats' Disease;Idiopathic Retinal Telangiectasia;Retinal Angiomatous Proliferation;Polypoidal Choroidal Vasculopathy;Pseudoxanthoma Elasticum;Pathological Myopia;Multi-focal Choroiditis;Rubeosis Iridis;Von Hippel Lindau Disease;BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)Drug: ranibizumab injection (0.5 mg)Manhattan Eye, Ear & Throat HospitalGenentech, Inc.Not recruiting18 YearsN/ABoth18Phase 1/Phase 2United States

先頭へ